Polypeptide derivative for promoting cell proliferation and preparation method and application thereof

Abstract

The invention relates to a polypeptide derivative for promoting cell proliferation and a preparation method and an application thereof. The structure of the polypeptide derivative is Nap-FFGGYGSSRRAPQT. The present invention also provides a preparation method of the polypeptide derivative. The polypeptide derivative is synthesized by adopting a FMOC-solid phase synthesis method. The present invention also provides an application of the polypeptide derivative in medicines for promoting cell proliferation. The derivative is simple to synthesize, the active self-assembled polypeptide can be synthesized by a solid-phase synthesis method, and the used raw materials are amino acids necessary for human bodies every day; secondly, due to self-assembly, the derivative can be slowly released in vivo, thereby remarkably solving the problem of low in-vivo retention rate caused by easy degradation of IGF-I protein by various proteases in vivo after injection; and most importantly, the derivative can be combined with an IGF-I protein receptor to stimulate downstream signal pathways, to promote endothelial cell proliferation, and to promote vascular repair and angiogenesis.

Description

technical field [0001] The invention belongs to the field of biomedicine, and relates to a polypeptide derivative, in particular to a polypeptide derivative that promotes cell proliferation, and a preparation method and application thereof. Background technique [0002] Insulin-like growth factor I (IGF-I) is a growth factor protein similar to insulin in humans. It plays a vital role in growth and development, metabolism and cell survival, and has a wide range of applications in clinical and life science research. [0003] In clinical practice, there are currently two drugs based on IGF-I protein approved by the US FDA for the treatment of adolescent growth failure (Growth Failiure) and Laron syndrome (Laron syndrome), namely Mecasermin (Mecasermin) ), which is recombinant human IGF-I protein (rhIGF-I); and Mecasermin rinfabate, which is a complex of recombinant human IGF-I protein and recombinant human IGFBP-3 protein (rhIGFBP-3). [0004] In addition to being used as a c...

AI Technical Summary

Problems solved by technology

[0007] First of all: the production cost of existing recombinant proteins is high, the production process is difficult to strictly control, the quality between batches is difficult to guarantee, and industrialization is difficult

[0008] Secondly, the transportation and storage conditions of recombinant proteins are harsh, which further increases their production costs and limits their scope of application

[0009] Again, for the protein itself, it is ineffective to directly inject IGF-I protein into the damaged organ, mainly due to its low retention rate in the tissue (small size: about 7.5KD)

In order to solve these problems, researchers have developed many methods to encapsulate IGF-I and deliver it to designated locations through biocompatible carriers, but none of these studies have achieved clinical application

Images